

APPENDIX

IN THE SPECIFICATION:

Please amend the table on page 13 as follows:

Table 1 – Amino acid substitutions in the KNT mutant strains

SEQ ID NO:	Residue No.	2 17	25	57	61	62	66	75	91	94	102 1	112 1	116	117	159	188 1	190 -	196	197	198	199 2	203 2	206 :	207 2	211 2	220 2	234 2	238 2	246
1	WT*	ΝН	D	М	Ε	Α	Н	٧	Q	S	Q	S	L	Ε	T	S	S	V	Κ	Q	S	S	D	Н	F	S	L	T	D
12	KT3-1	Υ						Α	R		R	Ρ	F					L									V	Α	
13	KT3-3		Ν	L	G	٧		Α		Р	R			G			L								Ļ				
14	KT3-5				G		Υ	Α	R	Ρ	R										Ρ						V		Ν
15	KT3-7	S			G		Υ	Α	R		R	Ρ	F				Т			L							٧		
2	KT3-11	K			G		Υ	Α	R		R	Ρ	F								Р				L				
<u>16</u>	KT3-12					T	Υ	Α	R	Р	Κ	Т			L	G			R		Р	Р						Α	
<u>17</u>	KT3-13				G		Υ	Α	R		R	Р	F								Р		V	Q					
18	KT-3-15	i			G		Υ	Α	R		R	Р	F								Р		V	Q		_			
19	KT3-16				G		Υ	Α	R	Р	K	Р									Ρ		V	Q		Р			
<u>20</u>	KT3-19			L			Υ	Α	R	Р	K	Р									P			Q_					
3	HTK	K		Ĺ	G	٧	Υ	Α	R	Р	R	Р	F								Р	Р	<u>V</u>	Q	<u>L</u>	<u> P</u>	V	Α	

IN THE CLAIMS:

1. A mutant kanamycin nucleotidyltransferase [having] <u>comprising the</u>
<u>sequence of SEQ ID NO:1 modified by at least</u> one [or more] point <u>mutation</u> [mutations]
selected from [a group consisting of] Met57Leu, [Ala62Val,] Ser94Pro, Ser203Pro,
Asp206Val, His207Gln, Ser220Pro, Ile234Val and Thr238Ala [as against the protein
comprising the amino acid sequence indicated by SEQ ID NO: 1], and having improved
thermostability as compared to SEQ ID NO:1.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLL

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

PATENT Customer No. 22,852 Application No. 09/697,186 Attorney Docket No. 04853.0048-00

- 2. A mutant kanamycin nucleotidyltransferase with improved thermostability [, wherein it comprises] as compared to SEQ ID NO:1, comprising the amino acid sequence indicated by SEQ ID NO:2. [SEQ ID NO: 2.]
- 3. The <u>mutant</u> kanamycin nucleotidyltransferase according to claim 1, <u>comprising</u> [wherein it comprises] the amino acid sequence indicated [in SEQ ID NO: 3.] <u>by SEQ ID NO:3.</u>

IN THE ABSTRACT:

It is desirable to have [To obtain a] selective <u>markers</u> [marker] suitable for screening of thermophilic bacteria such as *Thermus thermophilus*. *T. thermophilus* are good research materials for investigating the interrelation between enzyme structures and functions since they are stable at extreme pH, crystallize easily and are easy-to-handle.

[To provide a novel] <u>Novel mutants of *Staphylococcus aureus*</u> kanamycin nucleotidyltransferase with markedly improved thermostability <u>are disclosed</u>, <u>as well as</u> a selective marker using the same, and a screening method for thermophilic bacteria such as [*Thermus*] <u>T.</u> thermophilus using said selective marker.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT&
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400

www.finnegan.com

Table 1 – Amino acid substitutions in the KNT mutant strains

246	۵			z									
238	-	⋖					⋖					4	
234		>		>	>							>	
206 207 211 220 234	တ									۵		۵	
211	L											_	
207	ェ							ø	a.	ø	ø	ø	
506	۵							>	>	>	>	>	
203	S						ᇫ					۵	
661	S			_				n	Δ.	Д	اہ	۵	
94 102 112 116 117 159 188 190 196 197 198 199 203	ø			_	_		_		_	_			
, 261	ᅩ				_		œ						
96 1	1	_					_						
90 1	\ S	_											
88 1	S				_		ഗ						
59 1							٠.						
17 1			, D										
16 1	Ш		ഗ										
2 1		ш.			щ				ш			Ш	
2 11	ဟ	<u>α</u>			₾	Δ.	—	₾	۵	<u>α</u>	<u>α</u>	П	
10	a	œ	ď	œ	œ	œ	メ	œ	œ	ᅩ	ᅩ	2	
	ဟ		Φ	α			<u>α</u>				<u>α</u>	۵	
5 91	Ø	ď		œ		œ		œ	œ	ď		2	
3 75	>	⋖	⋖	⋖	⋖	⋖	⋖	⋖	⋖	∢	⋖	⋖	
5 66	エ			>	>	>	>	>	>	>	>	>	
1 62	4		>		_		—					>	
7 61	Ш		ഗ	G	ග	G		O	Ö	G		၂ဗ	
5 57	Σ		_									-	
, 25			Z										l
1,7	I	>			٠,								
ue 2	Z	_	က	S S	2	<u> </u>	2	5	15	9	6	X	
Residue 2 17 No.	*LM	KT3-1	KT3-:	KT3.	KT3-	KT3-1	KT3-1	KT3-1	KT-3-15	KT3-16	KT3-19	Ě	
SEQ	-	12	13	4	15	7	16	17	. 82	19	20	က	

KT3-15 has the same mis-sense mutation as KT3-13. These two mutants, share three silent mutations, however KT3-13's two silent mutations and KT3-15's one mutation are mutually specific to each. Therefore, it is clear that these two mutants are distinct clones.